Results 11 to 20 of about 242 (81)

Laboratory evaluation of the speed of kill of lotilaner (Credelio™) against Ixodes ricinus ticks on dogs [PDF]

open access: yesParasites and Vectors, 2017
Background With the geographical expansion of tick species and increased recognition of pathogens they transmit, there is a requirement for safe and rapidly effective control measures for dogs.
Jason Drake   +2 more
exaly   +7 more sources

Early onset of pre-lethal effects of lotilaner (Credelio®) on Amblyomma americanum ticks on experimentally infested dogs [PDF]

open access: yesParasites & Vectors, 2021
Background The speed with which acaricides paralyze and kill ticks is relevant to impeding pathogen transmission. The objective of this study was to assess early-onset lotilaner effects on the motility and weights of Amblyomma americanum ticks collected ...
Martha J. Wenger   +14 more
doaj   +6 more sources

Safety evaluation of lotilaner in dogs after oral administration as flavoured chewable tablets (Credelio™) [PDF]

open access: yesParasites and Vectors, 2017
Background Lotilaner (Credelio™, Elanco) is a novel isoxazoline that provides rapid speed of flea and tick knockdown which is sustained for at least 1 month following oral administration to dogs.
Emmanuelle A. Kuntz   +1 more
exaly   +7 more sources

Assessment of lotilaner (Credelio® CAT) for control of in-home Ctenocephalides felis infestations [PDF]

open access: yesParasites and Vectors
Background Flea infestations remain a major issue in veterinary medicine. Highly effective flea control for dogs and cats remains the foundation for eliminating infestations from homes and improving skin conditions associated with flea-feeding.
Brian H Herrin, William G Ryan
exaly   +6 more sources

Assessment of the onset of lotilaner (Credelio™) speed of kill of fleas on dogs [PDF]

open access: yesParasites and Vectors, 2017
Background Lotilaner (Credelio™) is the newest member of the novel isoxazoline chemical class to be developed to treat canine ectoparasitism. Administered orally, lotilaner is rapidly absorbed with peak blood levels occurring within 2 h post-treatment. A
Jason Drake   +2 more
exaly   +8 more sources

Laboratory evaluation of the efficacy and speed of kill of lotilaner (Credelio™) against Ctenocephalides felis on cats [PDF]

open access: yesParasites & Vectors, 2018
Background Lotilaner is approved for dogs as a chewable tablet formulation. It has separately been developed for oral administration in cats (Credelio™ chewable tablets for cats) to meet the need for an easy to use, safe and rapidly effective ...
Daniela Cavalleri   +3 more
doaj   +6 more sources

Laboratory evaluations of the immediate and sustained effectiveness of lotilaner (Credelio™) against three common species of ticks affecting dogs in Europe [PDF]

open access: yesParasites and Vectors, 2017
Background There is a continuing need for novel approaches to tick control in dogs. One such approach lies in the ability of lotilaner (Credelio™), an isoxazoline with a rapid onset of action, to provide sustained efficacy against ticks. Two studies were
Jason Drake   +2 more
exaly   +7 more sources

A randomized, controlled field study to assess the efficacy and safety of lotilaner flavored chewable tablets (Credelio™) in eliminating fleas in client-owned dogs in the USA [PDF]

open access: yesParasites and Vectors, 2017
Background Preclinical studies have shown that the novel isoxazoline, lotilaner (Credelio™, Elanco) administered orally to dogs, produces rapid flea and tick knockdown and sustained speed of kill for at least a month post-treatment with a wide safety ...
Jason Drake   +2 more
exaly   +7 more sources

Assessment of the speed of flea kill of lotilaner (Credelio™) throughout the month following oral administration to dogs [PDF]

open access: yesParasites and Vectors, 2017
Background Lotilaner (Credelio™, Elanco), a novel isoxazoline, is a systemic insecticide and acaricide that is rapidly absorbed following oral administration to dogs and has a half-life of 30 days.
Jason Drake   +2 more
exaly   +6 more sources

Home - About - Disclaimer - Privacy